Recently, we demonstrated the involvement of NLRP1 in the acquired resistance of metastatic melanoma cells to the chemotherapy temozolomide (TMZ) by amplifying IL-1β signaling and activating nuclear factor κB (NF-κB) activity [12]. Here, IL1B is linked to melanoma.